drugset / Trial / NCT05366166
Pembrolizumab Plus Olaparib in LA-HNSCC
Phase 2
Active not recruiting
45 enrolled
UNC Lineberger Comprehensive Cancer Center
Merck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research study is to evaluate the effectiveness of using a combination of pembrolizumab and olaparib when given before and after standard chemoradiation therapy in treating locally advanced head and neck squamous cell carcinoma. Pembrolizumab and olaparib are drugs that are approved for head and neck cancer treatment. However, FDA has not approved the use of these two drugs together in treating head and neck cancer.
Timeline
- Start
- 2022-09-02
- Primary completion
- 2027-01-21
- Completion
- 2030-11-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olaparib | Small molecule | 150 mg | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | 400 mg | Intravenous |
| Background | Cisplatin | Other / unclassified | 40 mg/m2 | Intravenous |